Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FHB
- Development stage
- Preclinical
- Lead developer
- Cerecin
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]FHB (also known as [18F]FBHB or CER-022) is an 18F-labeled radiolabeled ketone body analogue of beta-hydroxybutyric acid (specifically, (3S)-4-fluoro-3-hydroxybutyric acid). It is being developed as a diagnostic positron emission tomography (PET) neuroimaging tracer to quantify regional ketone body metabolism in the brain. Developed originally at the University of Alberta and licensed to Cerecin, [18F]FHB is designed to detect and monitor metabolic disturbances and bioenergetic deficits associated with neurodegenerative and neurological disorders, such as Alzheimer's disease, Parkinson's disease, migraine, and infantile spasms. The tracer enters cells via monocarboxylate transporters (MCTs) and serves as a metabolic probe analogous to [18F]FDG, which measures glucose metabolism.
- Other names
- (3R)-4-[18F]fluoro-3-hydroxybutyric acid(3S)-4-[18F]fluoro-3-hydroxybutyric acid(S)-[18F]FHB(S)-[18F]fluoro-hydroxybutyrate(S)-[18F]fluoro-hydroxybutyric acid[18F]FBHB[18F]fluoro-hydroxybutyrate[18F]fluoro-hydroxybutyric acid18FBHB
02
Targets
SLC16A1 (Mitochondrial Pyruvate Carrier)MCT2 (Monocarboxylate transporter 2)MCT4 (Monocarboxylate transporter 4)
Beyond the preview
Go deeper on [18F]FHB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]FHB.